YD Bio Limited Reports Full Year 2025 Results and Outlines 2026 Clinical Pipeline Milestones

YD Bio Limited (Nasdaq: YDES) reported financial results for the full year ended December 31, 2025. Net revenue increased 17% year-over-year to $596,817, driven by higher pharmaceutical sales volumes, including Keytruda. However, net loss widened significantly to $8.3 million compared to $1.4 million in 2024. This was primarily due to a $3.2 million change in fair value of warrant liabilities, a $1.1 million increase in R&D expenses for licensed patents, and higher staff and professional fees following its 2025 business combination. As of December 31, 2025, the company held $6.0 million in cash. Operationally, YD Bio completed CMC development for its Limbal Stem Cell (LSC) platform and filed Drug Master Files with the FDA. In 2026, the company plans to submit IND applications for Dry Eye Disease and Age-Related Macular Degeneration. Additionally, it is advancing its OkaiDx pancreatic cancer program toward an FDA Q-Submission and pursuing strategic M&A, including a merger with EG BioMed to integrate AI-driven oncology platforms.